
AstraZeneca trials show antibody drug more than 80% effective at preventing COVID-19
Fox News
COVID-19 vaccine maker AstraZeneca announced Thursday that its antibody drug is more than 80% effective at reducing risk of severe disease or death.
Analysis of the ongoing Provent trial with a six-month follow-up found that one 300- mg intramuscular dose of AZD7442 reduced the risk of developing symptomatic COVID-19 compared to placebo by 83%.
"The AZD7442 PROVENT trial is the first Phase III trial prospectively designed to evaluate a monoclonal antibody for pre-exposure prophylaxis of symptomatic COVID-19, with targeted inclusion of high-risk and immunocompromised participants. More than 75% of PROVENT participants at baseline had co-morbidities that put them at high risk for severe COVID-19 if they were to become infected, including people who are immunocompromised and may have a reduced immune response to vaccination," AstraZeneca wrote.

Pizza before tomatoes? Ancient Rome's version of America's favorite food looked nothing like today's
Ancient Rome pizza at Hungary restaurant features no tomatoes or mozzarella, using garum fish sauce and olive paste. Neverland Pizzeria's dish is limited-edition.












